Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro.
Although immunological tolerance to self Ags represents an important mechanism to prevent normal tissue injury, there is growing evidence that tolerance to tumor Ags, which often represent normal peripherally expressed proteins, is not absolute and can be effectively reverted. Prostate-specific Ag (PSA) is a self Ag expressed by both normal and malignant prostatic epithelium, and therefore offers a unique opportunity to examine the ability of self Ags to serve as specific CTL targets. In this study, we investigated the efficacy of autologous dendritic cells (DC) transfected with mRNA encoding PSA to stimulate CTL against PSA Ags in vitro. Ag in form of RNA carries the advantage to encode multiple epitopes for many HLA alleles, thus permitting induction of CTL responses among many cancer patients independent of their HLA repertoire. In this study, we show that PSA mRNA-transfected DC were capable of stimulating primary CTL responses against PSA Ags in vitro. The PSA-specific CTL did not cross-react with kallikrein Ags, a protein, which shares significant homology with PSA, suggesting that harmful autoimmune toxicity may not represent a significant problem with this approach. PSA RNA-transfected DC generated from male or female healthy volunteers or from cancer patients were equally effective in stimulating PSA-specific CTL in vitro, implying that neither natural tolerance to PSA Ags nor tumor-mediated T cell anergy may represent major barriers for CTL generation against the self Ag PSA. This study provides a preclinical rationale for using PSA RNA-transfected DC in active or adoptive immunization protocols.
Heiser
A
A
Division of Urology and Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.
Dahm
P
P
Yancey
D R
DR
Maurice
M A
MA
Boczkowski
D
D
Nair
S K
SK
Gilboa
E
E
Vieweg
J
J
D002454:Cell Differentiation; D002478:Cells, Cultured; D003602:Cytotoxicity, Immunologic / Q000235:genetics*; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D005260:Female; D006801:Humans; D007108:Immune Tolerance / Q000235:genetics; D007610:Kallikreins / Q000737:chemistry / Q000276:immunology; D008213:Lymphocyte Activation / Q000235:genetics*; D008297:Male; D010455:Peptides / Q000276:immunology; D017430:Prostate-Specific Antigen / Q000737:chemistry / Q000235:genetics* / Q000276:immunology; D011471:Prostatic Neoplasms / Q000276:immunology / Q000517:prevention & control; D012313:RNA / Q000235:genetics* / Q000276:immunology; D017386:Sequence Homology, Amino Acid; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014162:Transfection / Q000276:immunology* / Q000379:methods
D018984:Epitopes, T-Lymphocyte; D010455:Peptides; D012313:RNA; D007610:Kallikreins; D017430:Prostate-Specific Antigen